Section
Videos
27 pages in this section, most recently updated September 4, 2026. Each opens with a plain-English summary and cites its sources.
01 · Videos
Fact-check: an emergency physician's top five GLP-1 problems
You'll get: An ER doctor ranks the GLP-1 problems he sees: vomiting, dehydration and kidney injury, ketosis, muscle loss and low mood.
Nick Sterling, MD, PhD ranks what he sees in the emergency department: nausea and vomiting, dehydration and kidney injury, starvation ketosis, muscle loss and low mood. Useful clinical texture; not incidence data, and two sections lean on general evidence rather than GLP-1 trials.
Updated September 4, 2026
02 · Videos
Fact-check: Mayo Clinic Proceedings on tirzepatide in type 1 diabetes
You'll get: Two researchers summarise their chart review of tirzepatide in adults with type 1 diabetes and obesity.
Two Mayo research fellows summarise their retrospective study of tirzepatide in adults with type 1 diabetes and obesity. The numbers match the paper; the use is off-label and the study design limits what it can show.
Updated September 4, 202603 · Videos
FeaturedFact-check: NEJM's two-minute summary of the SELECT trial
You'll get: The journal's own summary of a trial of semaglutide in people with heart disease and obesity but no diabetes.
The journal's own two-minute summary of the SELECT heart trial. Every figure is from the paper; we add what it leaves out and who the result applies to.
Updated September 4, 202604 · Videos
Fact-check: Ohio State's 90-second answer to what a GLP-1 agonist is
You'll get: A hospital doctor explains in 87 seconds that the drug copies a gut hormone acting on appetite, fullness and blood sugar.
A hospital explainer that gets the mechanism right in under two minutes. What it compresses, what it cannot fit, and the label and trial sources behind each sentence.
Updated September 4, 202605 · Videos
FeaturedFact-check: the Veterans Health Administration's subcutaneous injection demonstration
You'll get: A government health video shows every step of injecting from a vial with a syringe, the format compounded drugs come in.
A government health system's step-by-step vial-and-syringe technique. Correct throughout for what it shows; here is what a person injecting a GLP-1 from a vial must add, especially about concentration and units.
Updated September 4, 202606 · Videos
FeaturedFact-check: Yale Medicine on how obesity medicine works
You'll get: A Yale doctor argues the brain defends a weight set point, which is why diets are usually regained.
A Yale physician explains the defended fat-mass set point and why medications and surgery succeed where lifestyle alone often cannot hold. A sound framework, presented without numbers; here are the numbers and the caveats.
Updated September 4, 202607 · Videos
Fact-check: Cleveland Clinic's one-minute SELECT result
You'll get: A trial investigator says semaglutide cut heart events by about 20 percent in people with existing heart disease.
A SELECT investigator gives the headline in 61 seconds: about 20 percent fewer cardiovascular events. Right, but relative; here are the absolute numbers, and a caption error to ignore.
Updated September 4, 202608 · Videos
FeaturedFact-check: Dr. Spencer Nadolsky on the top five GLP-1 side effects and what to do
You'll get: An obesity doctor covers nausea, constipation, reflux, diarrhoea and tiredness: when each shows up and what helps.
An obesity medicine physician on nausea, constipation, reflux, diarrhoea and fatigue: the time course, the food changes that help, and when his clinic adds medication. Matches the trial pattern; the medication steps need your own prescriber.
Updated September 4, 202609 · Videos
Fact-check: Endocrine Society journal club on tirzepatide's metabolic effects
You'll get: Three specialists discuss a lab study of how tirzepatide changes blood chemicals tied to insulin resistance.
Three endocrinologists discuss a lab study of tirzepatide's effect on blood chemistry. Accurate and careful, and of little use when choosing treatment.
Updated September 4, 202610 · Videos
FeaturedFact-check: Harvard's teaching video on GLP-1 agonists for weight loss
You'll get: A Harvard doctor walks through the trials that made two GLP-1 drugs weight-loss drugs.
A Harvard endocrinologist gives the trial numbers behind liraglutide and semaglutide in six minutes. Every figure checked, plus what changed since 2022.
Updated September 4, 202611 · Videos
Fact-check: Weber State University's insulin syringe demonstration
You'll get: A nursing teacher shows insulin syringe skills: air in first, scrub the top, read the units, push slowly.
A nursing skills video on drawing up and injecting insulin subcutaneously. The syringe handling transfers to any vial; the insulin-mixing section does not apply to GLP-1s and the 45-degree angle differs from pen labels.
Updated September 4, 202612 · Videos
Fact-check: Yale Medicine on medical therapies for weight management
You'll get: Yale clinicians describe the drugs as one part of a program, and stress that response varies widely from person to person.
Yale clinicians on incretin drugs as one part of a program, the wide variation in individual response, and combining medication with endoscopic procedures. Accurate and general; the response-variability point deserves the trial figures behind it.
Updated September 4, 202613 · Videos
Fact-check: Harvard's teaching video on prescribing GLP-1 agonists for weight loss
You'll get: A Harvard doctor covers who should and should not take these drugs, where to inject, pens and dose steps.
Indications, contraindications, cautions, injection sites, pen differences and titration for liraglutide and semaglutide, checked line by line against the Saxenda and Wegovy labels. What has changed since 2022.
Updated September 4, 202614 · Videos
Fact-check: Speed Pharmacology's incretin segment in Drugs for Diabetes
You'll get: A 2017 lecture explains why GLP-1 drugs exist: the body's own hormone is gone in minutes, so drugs were built to last.
A 2017 pharmacology lecture covers every diabetes drug class in 17 minutes. The incretin section is accurate and still a good primer; here is what a 2026 viewer needs to add.
Updated September 4, 202615 · Videos
Fact-check: the American Pharmacists Association's subcutaneous administration clip
You'll get: A four-minute pharmacist training clip shows a vaccine shot into the back of the upper arm.
A pharmacist-training video on subcutaneous injection into the back of the upper arm, filmed for vaccines. What carries over to a GLP-1 self-injection and what does not.
Updated September 4, 202616 · Videos
Fact-check: the Anesthesia Patient Safety Foundation on GLP-1s before anaesthesia
You'll get: GLP-1 drugs slow the stomach, so food can remain even after fasting, which matters before anaesthesia.
Case reports of a full stomach despite fasting, the June 2023 ASA guidance to hold weekly agents for a week, and gastric ultrasound as a bedside check. Accurate for its date; a 2024 multi-society statement has since changed the default advice.
Updated September 4, 202617 · Videos
FeaturedFact-check: two trialists interpret the tirzepatide data (CMHC)
You'll get: Two trial doctors discuss tirzepatide as of early 2023: results, dose steps, switching drugs and the birth control caution.
Dr. Anne Peters and Dr. Juan Frias discuss tirzepatide as of early 2023: trial results, dose escalation, switching from a GLP-1, the contraceptive caution and cardiovascular data. What has changed since, and what was the speaker's practice rather than the label.
Updated September 4, 202618 · Videos
Fact-check: Yale Medicine on lifestyle interventions for weight management
You'll get: Yale's team explains what diet, exercise, sleep and mood do: modest weight loss, but big health and maintenance gains.
Yale's weight management team on what diet, exercise, sleep and mood do and do not achieve. The 3 to 4 percent figure is at the low end of the trial literature; here is the range and why it varies.
Updated September 4, 202619 · Videos
Fact-check: Cleveland Clinic's 45-minute GLP-1 question and answer
You'll get: A hormone doctor answers common patient questions for 45 minutes. The side-effect section is the best part.
An endocrinologist answers the questions patients ask most: how the drugs work, how long to take them, how much weight to expect, how common the side effects are, and what is rare but real. Sound throughout; a few figures are rounded and one analogy oversells the stomach.
Updated September 4, 202620 · Videos
Fact-check: Johns Hopkins Medicine's podcast on how GLP-1s work and who they help
You'll get: An obesity doctor explains how muscle declines with age and why protein and strength training matter during weight loss.
A 38-minute conversation with an obesity medicine physician at Johns Hopkins. Strong on body composition and long-term framing; we add the trial numbers and check the compounding section against the FDA's current position.
Updated September 4, 202621 · Videos
Fact-check: Mayo Clinic Minute on weaning off weight-loss medications
You'll get: A one-minute news piece says stopping early carries a high chance of regaining weight, and to talk to a clinician first.
A one-minute news piece on stopping: high chance of regain if you stop early, appetite signals return, talk to a clinician first. Right in outline; here are the withdrawal trials that put numbers on it.
Updated September 4, 202622 · Videos
Fact-check: Stanford Health Care's hour on GLP-1 receptor agonists, the truth behind the trend
You'll get: A Stanford pharmacist walks through the biology, every GLP-1 product, and the diabetes, heart and kidney trials.
A clinical pharmacist walks through the biology, every GLP-1 drug and the major trials. Thorough and mostly right; some numbers drift, one badly.
Updated September 4, 202623 · Videos
Fact-check: TCOYD's Mounjaro versus Ozempic showdown
You'll get: Two diabetes doctors score tirzepatide against semaglutide in eight areas. Their trial reasoning holds up.
Two endocrinologists from the nonprofit Taking Control Of Your Diabetes score tirzepatide against semaglutide in eight categories. The trial reasoning is sound; two pieces of practical advice are personal opinion that we do not endorse.
Updated September 4, 202624 · Videos
Fact-check: the Endocrine Society podcast on compounded obesity medications
You'll get: A hormone doctor explains what compounding is, why compounded GLP-1s are not FDA approved, and how dose mix-ups happen.
An NYU endocrinologist explains compounding, the shortage rules, why compounded GLP-1s are not FDA approved and the dosing confusion they cause. Largely accurate and sponsored by Eli Lilly; the quantitative claims are unnamed on air and we could only partly trace them.
Updated September 4, 202625 · Videos
Fact-check: Stanford Health Care's dietitian webinar on managing GI side effects
You'll get: A dietitian gives an hour on nausea, vomiting, constipation and diarrhoea with week-by-week trial percentages.
An hour on nausea, vomiting, constipation and diarrhoea with the trial percentages by week and the food strategies that help. The numbers trace to a published review; here is where they come from and what a tirzepatide user should add.
Updated September 4, 202626 · Videos
Fact-check: Stanford Medicine's three minutes on what the science says about GLP-1s
You'll get: Stanford faculty summarise benefits for blood sugar, heart, kidneys and sleep apnoea, and discuss weight bias.
Several Stanford faculty on benefits, side effects and weight bias in a short news-style piece. Mostly right; one cardiovascular figure is broader than the trial it seems to rest on.
Updated September 4, 202627 · Videos
FeaturedFact-check: UCSF grand rounds on anti-obesity medications, beyond the scale
You'll get: A clinic director reviews every approved weight drug with one- and two-year results, and sets goals by percent lost.
UCSF's weight clinic director on goals by percent lost, every approved drug's one- and two-year results, and side effects. Dense and well sourced.
Updated September 4, 2026